| REVIEW ARTICLE |
|
| Year : 2023 | Volume
: 13
| Issue : 1 | Page : 3-12 |
|
|
Dry eye disease: A review of anti-inflammatory therapies
Annie Nguyen1, Ajay Kolluru2, Talia Beglarian2
1 Keck School of Medicine of University of Southern California; Department of Ophthalmology, USC Roski Eye Institute, Los Angeles, California, USA
2 Keck School of Medicine of University of Southern California, Los Angeles, California, USA
Correspondence Address:
Dr. Annie Nguyen
1450 San Pablo Street, Suite 4700, Los Angeles, California 90033
USA
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/2211-5056.369606
|
|
|
Dry eye disease (DED) is a common chronic ocular disease. DED can have a significant impact on visual function, causing disturbances to comfort, daily activities, and general quality of life. The varied nature of DED makes it difficult to point to a specific cause of the syndrome. However, current literature agrees that the inflammation of the cornea and conjunctiva plays a major role in its pathogenesis. Therapies targeted toward inflammation have shown varied success in the treatment of DED. The purpose of this review is to provide an overview of the prevalence and inflammatory pathophysiology of DED and discussion of the available anti-inflammatory therapies including the following: Nonsteroidal anti-inflammatory drugs, corticosteroids, and other hormonal therapies, nonsteroidal immunomodulators, biological tear replacement, antibiotics, dietary supplements, tea tree oil, and intense pulsed light.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
